Latest filing published 05 Mar 2026 for NovoCure Ltd, €202k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Ashley Cordova, listed as finance chief, appears in our data through filings on Novocure Ltd shares, published by SEC (Form 4). We count 67 filings; the first trade dates from 1 September 2020 and the latest from 4 March 2026.
On the open market, the record shows 1 purchase worth €855k and 29 sales worth €5.0M. On balance, insiders were net sellers of €4.2M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 21 share grants and 14 option exercises.
Most recently, on 5 March 2026, the filings show a share grant worth €202k in Novocure Ltd. The last purchase on record was published on 8 September 2025, which is 411 days ago. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 32 declarations